Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) EBT Margin: 2022-2025

Historic EBT Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to 205,800.00%.

  • Taysha Gene Therapies' EBT Margin rose 20713194.00% to 205,800.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,495.62%, marking a year-over-year decrease of 67459.00%. This contributed to the annual value of -1,015.49% for FY2024, which is 53743.00% down from last year.
  • Per Taysha Gene Therapies' latest filing, its EBT Margin stood at 205,800.00% for Q3 2025, which was up 16,507.16% from -1,254.33% recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' EBT Margin peaked at 205,800.00% during Q3 2025, and registered a low of -1,788.31% during Q2 2024.
  • Moreover, its 3-year median value for EBT Margin was -873.76% (2025), whereas its average is 17,892.33%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by 786,075bps in 2023, then skyrocketed by 20,713,194bps in 2025.
  • Over the past 4 years, Taysha Gene Therapies' EBT Margin (Quarterly) stood at 4,220.08% in 2022, then plummeted by 463,734bps to -417.26% in 2023, then crashed by 48,551bps to -902.77% in 2024, then skyrocketed by 20,713,194bps to 205,800.00% in 2025.
  • Its last three reported values are 205,800.00% in Q3 2025, -1,254.33% for Q2 2025, and -873.76% during Q1 2025.